Personalized mRNA vaccine shows promise in reducing melanoma return: Research
Study results released on Monday revealed that a personalized mRNA vaccine manufactured by Moderna and Merck has shown promise in reducing the return of melanoma, the deadliest form of skin cancer. The findings were unearthed by researchers who tracked the impact of the vaccine five years after individuals participated in a Phase 2b study. A…
Study results released on Monday revealed that a personalized mRNA vaccine manufactured by Moderna and Merck has shown promise in reducing the return of melanoma, the deadliest form of skin cancer. The findings were unearthed by researchers who tracked the impact of the vaccine five years after individuals participated in a Phase 2b study. A…
Study results released on Monday revealed that a personalized mRNA vaccine manufactured by Moderna and Merck has shown promise in reducing the return of melanoma, the deadliest form of skin cancer. The findings were unearthed by researchers who tracked the impact of the vaccine five years after individuals participated in a Phase 2b study. A…
The full story continues on The Hill.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.